BRUKER CORPORATION (NASDAQ: BRKR)

Q3 2026 Earnings Presentation

November 4, 2026

Frank H. Laukien, President & Chief Executive Officer
Gerald Herman, Executive Vice President & Chief Financial Officer
Joe Kostka, Director, Investor Relations



Safe Harbor Statement

Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our fiscal year 2026 and beyond financial outlook, our outlook for reported revenue growth, organic revenue growth, M&A revenue growth contributions, CER currency revenue growth, margin improvements, foreign currency translation revenue impact, EPS, non-GAAP EPS, and CER non-GAAP EPS growth; management's expectations for the impact of foreign currency and acquisitions; the effects of our expanded cost savings initiatives; and for future financial and operational performance and business outlook; future economic conditions. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, (1) the length and severity of any disruption in US academic and government markets, a potential recession, and global economic conditions, (2) the impact of supply chain challenges, including inflationary pressures, or shortages or price spikes in high-performance memory chips or in liquid Helium, (3) the impact of wars, blockades, geopolitical instability and tensions and any sanctions, (4) the ongoing tensions between the United States and China, tariff increases or uncertainties and tariff and trade policy changes and restrictions, (5) continued volatility in the capital markets, (6) the impact of increased interest rates, (7) the integration and assumption of liabilities of businesses we have acquired or may acquire in the future, (8) our restructuring and cost-control initiatives, (9) changing technologies, product development and market acceptance of our products, (10) the cost and pricing of our products, manufacturing and outsourcing, competition, dependence on collaborative partners, key suppliers and third party distributors, capital spending and government funding policies, (11) changes in governmental regulations, intellectual property rights, and litigation, (12) the impact of foreign currency exchange rates, (13) our ability to service our debt obligations and fund our anticipated cash needs, (14) the effect of a concentrated ownership of our common stock, (15) the loss of key personnel, (16) payment of future dividends, (17) the impact (if any) of macroeconomic issues, including uncertainties related to trade policies or tariff regulations, and (18) other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2025, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by applicable law.

© 2026 Bruker



Q3 2026

Business Update


Q3 2026: Significant Non-GAAP Operating Margin Expansion and Non-GAAP EPS Growth

Q3 2026 Performance; Year-over-Year Changes


- Revenue increase of $13.5M, or 1.6%
  - Organic growth of +0.7%, with BSI down -0.4% and BEST up +11.8%
  - M&A contribution of +1.7%, with CER growth of +2.4%
  - FX headwind of -0.8%
- Non-GAAP gross margin 51.3%, up 120 bps
- Non-GAAP operating margin 16.3%, up 400 bps
- GAAP Loss per Share: -$0.81
- Non-GAAP EPS: $0.56, up +24.4%
- BSI Book-to-Bill >1.0x

Q3 Financials

Revenues [$M]



Non-GAAP EPS



Reconciliations of non-GAAP to GAAP financial measures are available in our earnings press release and at the end of this presentation.

© 2026 Bruker


Q3-26 YTD: Meaningful Non-GAAP Margin Expansion and Non-GAAP EPS Growth

Q3 2026 YTD Performance; Year-over-Year Changes


- Revenue increase of $76.6M, or 3.1%
  - Organic decline of -0.3%, with BSI down -1.0% and BEST up 8.3%
  - M&A contribution of +1.9%, with CER growth of +1.6%
  - FX tailwind of +1.5%
- Non-GAAP gross margin 51.1%, up 110 bps
- Non-GAAP operating margin 13.6%, up 220 bps
- GAAP Loss per Share: -$1.20
- Non-GAAP EPS: $1.36, up +10.6%
- BSI organic bookings up mid single digits %; BSI Book-to-Bill >1.0x

Q3-YTD Financials

Revenues [$M]



Non-GAAP EPS



Reconciliations of non-GAAP to GAAP financial measures are available in our earnings press release and at the end of this presentation.

© 2026 Bruker

Bruker Groups - YTD CER Performance YoY





Bruker BioSystems Group


- BioSystems revenue up low single digits %
- Strong Academic Medical and Biopharma revenue growth; softness in other aca/gov, and food testing
- Strong revenue growth in IR/Raman spectroscopy; softness in NMR
- Solid mass spectrometry order growth from acquisition of TOFWERK in Switzerland

Bruker Microbiology & Infection Diagnostics (BMID) Group

- BMID revenue up low single digits %
- Strength in Europe; softness in APAC and US
- Robust Molecular Dx revenue and order growth
- Modest growth in Microbiology

© 2026 Bruker

Bruker Groups - YTD CER Performance YoY



Bruker NANO Group

- NANO CER revenue down low single digits %
- Strong Semi and biopharma revenues; weakness in aca/gov and industrial
- Revenue growth in US and Europe offset by softer APAC
- Strong AI-driven orders for memory and advanced packaging semi metrology tools



Bruker Energy & Supercon Technologies (BEST) Segment

- BEST CER revenue up 8%, net of intercompany eliminations
- Robust revenue growth at Research Instruments (RI), solid growth in superconductors
- Outstanding order growth from multi-year contracts for superconducting wire, fusion energy technologies, and high-energy physics tools

© 2026 Bruker

MIMETAS: A leading humanized Organ-on-a-Chip & NAM platform

Acquisition expands preclinical solutions for drug discovery and disease biology research



- MIMETAS humanized microphysiological systems include organ-on-a-chip (OoC) models, also known as New Approach Methodologies (NAMs)
- MIMETAS combines physiological microfluidic 3D human cell organoids with membrane-less OoC interfaces
- NAMs complement preclinical animal testing
- MIMETAS synergies with Bruker multiomics, spatial biology and preclinical imaging tools for disease biology research, drug development and AI frontier models

Annual revenues ~$10M, expected to grow in the double digits %, with accretive gross margins

© 2026 Bruker

iHUPO News: Advancing Functional Proteomics with Novel Workflows

For Post-Genomic Drug Discovery and Disease Biology 2.0 Research

Novel MultiDIA method on timsUltra

- more peptides and protein groups
  - more isoforms, sequence variants, and protein regions missed by other MS-based or by affinity methods



Advanced glycopeptide characterization on timsOmni

- Fast, sensitive and selective trapped electron-based glycopeptide fragmentation

Oligonucleotide and native RNA analysis on timsOmni

- Native top-down analysis of folded RNA structures
- Advanced oligonucleotide characterization for RNA drug targets or RNA drugs



© 2026 Bruker



Q3 2026

Financial Update

Q3 2026 Selected Non-GAAP Financial Measures[1]

[$ m, except EPS]	Q3 2026	Q3 2025	Δ
Total Revenues	874.0	860.5	1.6%
Gross Profit	448.3	430.9	4.0%
Margin (% of revenues)	*51.3%*	*50.1%*	*120 bps*
SG&A	(213.8)	(227.1)	(5.9%)
(% of revenues)	*24.5%*	*26.4%*	
R&D	(92.0)	(98.3)	(6.4%)
(% of revenues)	*10.5%*	*11.4%*	
Operating Income	142.6	105.9	34.7%
Margin (% of revenues)	*16.3%*	*12.3%*	*400 bps*
Tax Rate	28.4%	24.4%	400 bps
Net Income[2]	86.3	67.9	27.1%
EPS	$0.56	$0.45	24.4%
Shares Outstanding	153.2	152.0	0.8%

Comments (year-over-year)

- Revenue increase of +1.6%
  - Organic revenue growth +0.7%
  - BSI organic decline of -0.4%; BEST organic growth of 11.8%
- Gross margin increase of 120 bps
- Operating margin increase of 400 bps:
  - Driven by cost savings +300 bps and mix +90 bps
- Non-GAAP EPS of $0.56, up 24.4%

[1]Reconciliations of non-GAAP to GAAP financial measures are available in our earnings press release and at the end of this presentation.
[2]Attributable to Bruker common shareholders, Sum of items may not total due to rounding

© 2026 Bruker

Q3-26 YTD Selected Non-GAAP Financial Measures[1]

[$ m, except EPS]	YTD 2026	YTD 2025	Δ
Total Revenues	2,535.9	2,459.3	3.1%
Gross Profit	1,296.7	1,229.0	5.5%
Margin (% of revenues)	*51.1%*	*50.0%*	*110 bps*
SG&A	(664.1)	(654.4)	1.5%
(% of revenues)	*26.2%*	*26.6%*	
R&D	(287.6)	(295.6)	(2.7%)
(% of revenues)	*11.3%*	*12.0%*	
Operating Income	345.3	279.6	23.5%
Margin (% of revenues)	*13.6%*	*11.4%*	*220 bps*
Tax Rate	27.0%	25.5%	150 bps
Net Income[2]	208.7	187.0	11.6%
EPS	$1.36	$1.23	10.6%
Shares Outstanding	152.9	152.0	0.6%

Comments (year-over-year)

- Revenue increase of 3.1%
  - BSI organic decline of -1.0%; BEST organic growth of 8.3%
- Gross margin increase of 110 bps
- Operating margin increase of 220 bps:
  - Driven by cost savings +280 bps, net US tariffs +60 bps, partially offset by volume/mix -50 bps and FX headwinds of -70 bps
- Non-GAAP EPS of $1.36, increase of 10.6%, including FX headwind of $0.05

[1]Reconciliations of non-GAAP to GAAP financial measures are available in our earnings press release and at the end of this presentation.
[2]Attributable to Bruker common shareholders, Sum of items may not total due to rounding

© 2026 Bruker

Q3 2026 Selected Cash Flow And Balance Sheet Measures

[$M]	Q3 2026	Q3 2025	Δ
GAAP Net (Loss) Income	(109.7)	(58.5)	(51.2)
Depreciation & amortization	54.1	55.7	(1.6)
Changes in working capital	(18.0)	(92.2)	74.2
Other items	191.8	61.8	130.0
Operating cash flow	118.2	(33.2)	151.4
Capital expenditures	(21.5)	(20.9)	(0.6)
Free cash flow (non-GAAP)	96.7	(54.1)	150.8

[$M]	Q3 2026	Q2 2026	Δ
Cash, Equivalents & Short-term Investments	$119.7	$184.9	(35.3%)
Net (Debt)/ Cash	$ (1,597.6)	$ (1,641.8)	(2.7%)
WC-to-revenue ratio	0.42	0.42	___

Comments (year-over-year)

- Free cash flow up +$151M yoy, driven by higher net income, excluding non-cash impairment of goodwill, and improved working capital
- Net leverage ratio of 2.4x as of September 30th
  - Debt repayments of $58M in Q3-26

© 2026 Bruker

FY 2026 Outlook

Updating FY 2026 Financial Outlook for Currency (as of November 4th, 2026)

FY 2026 Guidance (year-over-year %s)

Revenue	**$3.52B to $3.56B**
Reported Revenue Growth	**+2.5% to +3.5%**
Organic revenue growth	***+1% to +2%***
M&A revenue contribution	***approx. 1.5%***
CER revenue growth	***+2.5% to +3.5%***
Non-GAAP EPS	**$2.10 to $2.15**
Reported EPS Growth	**+15% to +17%**


Non-GAAP Assumptions & YoY Estimates

- FY26 operating margin up 250-300 bps
- FX impact:
  - Neutral to revenue
  - Headwind to OPM ~50 bps
  - Headwind to EPS of ~$0.05
- Effective tax rate of 27.5%
- CAPEX: ~$110M
- FX assumptions (rates as of September 30, 2026):
  - EUR = 1.13 USD; CHF = 1.20 USD; JPY = 0.0064 USD

© 2026 Bruker

Supplementary Financial Information*

* For preliminary financial statements, GAAP to Non-GAAP reconciliations, and other supplementary financial information, please refer to our Q3 2026 Earnings Press Release issued November 4th, 2026.


BRUKER